BBNBonkers Broadcasting NetworkSaturday, October 10, 2026Sat, Oct 10Watch live

U.S.

Genmab, AbbVie Lymphoma Data Lifts Epkinly Outlook

On air: Hank Ledger on The Closing Bell
Published

At a glance

  • First reported by Seeking Alpha: “Genmab, AbbVie data boosts Epkinly as first-line B-cell lymphoma treatment”.
  • Covered on BBN on Monday, October 5, 2026, at 3:47 PM ET on The Closing Bell, by Hank Ledger.
  • Topics: AbbVie, Genmab.
  • BBN covered this story before: Genmab, AbbVie Lymphoma Drug Hits Phase 3 Goal (October 5).

The real story

The reporting behind this segment. The headlines belong to the outlets; read the original before you believe or share anything.

  • Seeking AlphaGenmab, AbbVie data boosts Epkinly as first-line B-cell lymphoma treatment
▶ Watch BBN liveMore U.S. →

The story so far

  1. Genmab, AbbVie Lymphoma Drug Hits Phase 3 Goal · GlobeNewswire Inc.
  2. Genmab, AbbVie Lymphoma Data Lifts Epkinly Outlook (this story)
  3. AbbVie Cuts Guidance; Bond Rout Draws Savers · Benzinga
  4. AI Chips Surge, AbbVie Cancer Combo, Cowbell Mystery · Bloomberg.com
  5. Europe Climbs as Genmab Jumps and Bond Yields Retreat · Reuters
  6. Senegal Swaps, U.S. Growth at 2.2%, Genmab Climbs · Bloomberg.com

From the archive: everything BBN aired on Monday, October 5, 2026 · the U.S. archive · all months

More in U.S.

All U.S. →